Chemotherapy-Induced Cardiotoxicity With Frontline BV-AVD for Hodgkin Lymphoma

Area of Science:

• Oncology
• Pharmacology
• Cardiology

Background:

• Brentuximab vedotin (BV) combined with chemotherapy is a recognized treatment for Hodgkin Lymphoma (HL).
• This regimen is known to increase risks of peripheral neuropathy and neutropenia.
• Emerging data suggest potential for novel and unexpected toxicities with increased utilization of BV.

Purpose of the Study:

• To report a case of cardiotoxicity associated with brentuximab vedotin and chemotherapy in Hodgkin Lymphoma treatment.
• To underscore the importance of vigilant monitoring for adverse events during this therapy.
• To advocate for further investigation into the risk factors, mechanisms, and long-term safety of BV-based regimens.

Main Methods:

• Case report presentation.
• Review of clinical presentation and treatment course.
• Literature review on brentuximab vedotin toxicity.

Main Results:

• The patient developed cardiotoxicity during BV-chemotherapy treatment for Hodgkin Lymphoma.
• This adverse event was unexpected and highlights a less common toxicity profile.
• The case emphasizes the need for proactive cardiac assessment in patients receiving this therapy.

Conclusions:

• Brentuximab vedotin-based chemotherapy can induce significant cardiotoxicity.
• Vigilant monitoring for cardiac adverse events is crucial for patients undergoing this treatment.
• Further research is warranted to elucidate the mechanisms and long-term implications of BV-induced cardiotoxicity.